Stock Events

Stock Events

Search...

Galapagos NV

€27.4

187

+€0.2+0.74% Today

Statistics

Day High

27.4

Day Low

27.4

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

1.77B

P/E Ratio

54.58

Dividend Yield

-

Dividend

-

Upcoming

Earnings

30OctExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.97

-0.52

0.94

2.39

Expected EPS

-0.12181143546968001

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GXEA.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.

Gilead Sciences

Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.

AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.

Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.

Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.

Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.

Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.

Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.

AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Show more...

CEO

Dr. Paulus A. Stoffels M.D., Ph.D.

Employees

683

Country

US

ISIN

US36315X1019

WKN

000A0YGNJ

Listings